Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alfa for chronic myeloid leukemia.

Michele Baccarani1, Domenico Russo, Gianantonio Rosti

  • 1Institute of Hematology and Medical Oncology L. and A. Seràgnoli, University of Bologna and S.Orsola Hospital, Bologna, Italy.

Seminars in Hematology
|February 4, 2003
PubMed
Summary

Interferon-alfa (IFNalpha) is a first-line treatment for chronic myeloid leukemia (CML), offering significant survival benefits over chemotherapy. Achieving early responses, especially in low-risk patients, leads to durable outcomes and long-term survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine Release Syndrome after Haploidentical Transplantation is Associated with Improved Survival Without Increasing Transplant-Related Mortality.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same author

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same author

Mesotherapy in Pain Management in Primary Care: A Narrative Review and Practice-Oriented Appraisal.

La Clinica terapeutica·2026
Same author

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Bone marrow transplantation·2026
Same author

Mogamulizumab as Bridge to Thiotepa-Based Allogeneic Haematopoietic Stem Cell Transplantation in Sézary Syndrome: A Single-Centre Experience.

EJHaem·2026

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Interferon-alfa (IFNalpha) is the established first-line therapy for chronic myeloid leukemia (CML).
  • IFNalpha significantly prolongs survival compared to conventional chemotherapy (CHT).
  • Treatment benefits and response rates are higher in low-risk CML patients.

Purpose of the Study:

  • To evaluate the efficacy of IFNalpha in treating CML.
  • To identify optimal response criteria for IFNalpha therapy.
  • To explore potential combination therapies and future research directions.

Main Methods:

  • Analysis of patient outcomes based on risk stratification.
  • Assessment of hematologic and cytogenetic response rates.
  • Review of potential synergistic effects with other agents and treatments.

Related Experiment Videos

Main Results:

  • Complete hematologic response (CHR) within 3-6 months and complete cytogenetic response (CCgR) thereafter yield the best outcomes in low-risk patients.
  • Cytogenetic responses (CgRs) to IFNalpha are stable and durable.
  • Approximately 50% of complete responders achieve long-term survival.

Conclusions:

  • IFNalpha provides significant survival advantages for CML patients, particularly when early and complete responses are achieved.
  • Further research into the mechanisms of IFNalpha action is warranted.
  • Investigating combination therapies with novel agents may enhance therapeutic outcomes.